Skip to main content

Effects of a general practitioner-led brief narrative exposure intervention on symptoms of post-traumatic stress disorder after intensive care (PICTURE): multicentre, observer blind, randomised controlled trial.

BMJ (Clinical research ed.)2025-05-08PubMed
Total: 82.5Innovation: 7Impact: 0Rigor: 0Citation: 0

Summary

In 319 ICU survivors with PTSD symptoms, a brief GP-led narrative exposure intervention reduced PDS-5 scores by 4.7 points at 6 months and 5.4 points at 12 months versus enhanced usual care, though below the pre-specified MCID of 6 points. Benefits extended to depression, health-related quality of life, and disability, with high follow-up retention.

Key Findings

  • At 6 months, PDS-5 decreased by a mean 4.7 points versus control (95% CI 1.6 to 7.8; P=0.003; d=0.37).
  • At 12 months, PDS-5 decreased by 5.4 points (95% CI 1.8 to 9.0; P=0.003; d=0.41), indicating sustained benefit.
  • Secondary outcomes showed improvements in depression, health-related quality of life, and disability.
  • Follow-up completion was high (85% at 6 months; 77% at 12 months); trial was registered (NCT03315390).

Clinical Implications

Post-ICU follow-up programs can integrate brief GP-led narrative exposure with nurse contacts to reduce PTSD symptoms and improve patient-centered outcomes; however, expectations should be tempered given effects just below MCID.

Why It Matters

This pragmatic, multicentre, observer-blind RCT in a top-tier journal demonstrates a scalable primary-care intervention that addresses post-ICU mental health, a major survivorship gap.

Limitations

  • Effect size did not exceed the predefined minimal clinically important difference
  • Self-reported PTSD scale and healthcare system context (Germany) may limit generalizability

Future Directions

Evaluate implementation at scale in diverse health systems, refine the intervention dose/timing, and test combinations with digital tools or trauma-focused therapies to achieve or exceed MCID.

Study Information

Study Type
RCT
Research Domain
Treatment
Evidence Level
I - Multicentre, observer-blind randomized controlled trial
Study Design
OTHER